← Eichor
Study identifier: NCT06911736 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Effect of the Postoperative Trendelenburg Position on Chronic Subdural Hematoma Recurrence

Condition: Chronic Subdural Hematoma · Trendelenburg · Recurrence  ·  Sponsor: Universidad de Antioquia

PhaseNA
Planned participants254
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

Objective: Determine the effect of the postoperative trendelenburg position on the recurrence of chronic subdural hematoma (CSH) in patients undergoing surgery. Materials and Methods: An open-label, randomized, controlled clinical trial was conducted in three hospitals in Medellín. Patients with CSH were enrolled and assigned to the trendelenburg position (30° leg elevation and 10° head tilt) or a flat bed for 24 hours postoperatively. CSH recurrence was measured at 3 months, along with functional outcome (modified Rankin scale), adverse events, and comfort (Likert scale).

This description comes directly from the study's public registry record.

Talk to the study team

Jorge H Montenegro, Neurosurgery resident  ·  +573117727801  ·  montenegromjh@gmail.com

Always discuss trial participation with your own doctor first.

Locations (3)

Clinica CESMedellín, Antioquia, ColombiaRecruiting
Hospital San Vicente FundaciónMedellín, Antioquia, ColombiaRecruiting
Instituto Neurologico de ColombiaMedellín, Antioquia, ColombiaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06911736